IL302174A - Compounds and methods for the treatment of eye disorders - Google Patents

Compounds and methods for the treatment of eye disorders

Info

Publication number
IL302174A
IL302174A IL302174A IL30217423A IL302174A IL 302174 A IL302174 A IL 302174A IL 302174 A IL302174 A IL 302174A IL 30217423 A IL30217423 A IL 30217423A IL 302174 A IL302174 A IL 302174A
Authority
IL
Israel
Prior art keywords
substituted
radical
alkyl
compound
heteroalkyl
Prior art date
Application number
IL302174A
Other languages
English (en)
Hebrew (he)
Original Assignee
Azura Ophthalmics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azura Ophthalmics Ltd filed Critical Azura Ophthalmics Ltd
Publication of IL302174A publication Critical patent/IL302174A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL302174A 2020-10-21 2021-10-20 Compounds and methods for the treatment of eye disorders IL302174A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063094808P 2020-10-21 2020-10-21
PCT/IB2021/000708 WO2022084739A1 (en) 2020-10-21 2021-10-20 Compounds and methods for the treatment of ocular disorders

Publications (1)

Publication Number Publication Date
IL302174A true IL302174A (en) 2023-06-01

Family

ID=81290138

Family Applications (1)

Application Number Title Priority Date Filing Date
IL302174A IL302174A (en) 2020-10-21 2021-10-20 Compounds and methods for the treatment of eye disorders

Country Status (10)

Country Link
US (1) US20230399317A1 (https=)
EP (1) EP4232034A4 (https=)
JP (1) JP2023546452A (https=)
KR (1) KR20230110516A (https=)
CN (1) CN116635032A (https=)
AU (1) AU2021365530A1 (https=)
CA (1) CA3196146A1 (https=)
IL (1) IL302174A (https=)
MX (1) MX2023004538A (https=)
WO (1) WO2022084739A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024100454A2 (en) * 2022-11-11 2024-05-16 Azura Ophthalmics Ltd. Composition and methods for improving signs and symptoms of ocular disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2830024T3 (es) * 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
US20090257957A1 (en) * 2008-04-15 2009-10-15 John Burnier Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
BR112015014367B1 (pt) * 2012-12-19 2022-11-22 Novartis Ag Composição inibidora de lfa-1, método para estabilizar a dita composição e uso da mesma para tratar uma doença ocular
US9463201B2 (en) * 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
US10688122B2 (en) * 2015-09-28 2020-06-23 Azura Ophthalmics Ltd. Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
JP2019513775A (ja) * 2016-04-19 2019-05-30 アズーラ オフサルミックス エルティーディー. 角化症の処置のための組成物
EP3600272A4 (en) * 2017-03-29 2021-01-13 Azura Ophthalmics Ltd. MEANS OF INCREASING LIPID SECRETION OF THE MEIBOMAN GLAND
WO2018212846A1 (en) * 2017-05-19 2018-11-22 Ocugen, Inc. Ophthalmic compositions and methods of use
US20180333357A1 (en) * 2017-05-19 2018-11-22 Ocugen, Inc. Nanoemulsions with anti-inflammatory activity
WO2019053607A1 (en) * 2017-09-18 2019-03-21 Glenmark Pharmaceuticals Limited PROCESS FOR PREPARING LIFITEGRAST
US11001574B2 (en) * 2017-11-17 2021-05-11 Medichem S.A. Process to obtain a tetrahydroisoquinoline derivative
WO2020212755A1 (en) * 2019-04-18 2020-10-22 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
JP7700045B2 (ja) * 2019-04-18 2025-06-30 アズーラ オフサルミックス エルティーディー. 眼障害を処置するための化合物および方法

Also Published As

Publication number Publication date
MX2023004538A (es) 2023-06-19
KR20230110516A (ko) 2023-07-24
CN116635032A (zh) 2023-08-22
AU2021365530A1 (en) 2023-06-15
EP4232034A4 (en) 2024-12-04
CA3196146A1 (en) 2022-04-28
JP2023546452A (ja) 2023-11-02
EP4232034A1 (en) 2023-08-30
AU2021365530A9 (en) 2024-02-08
WO2022084739A1 (en) 2022-04-28
US20230399317A1 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
US11643429B2 (en) Compounds and methods for the treatment of ocular disorders
US11634411B2 (en) Compounds and methods for the treatment of ocular disorders
IL302173A (en) Compounds and methods for the treatment of ocular disorders
AU2020259996B2 (en) Compounds and methods for the treatment of ocular disorders
WO2022084747A1 (en) Compounds and methods for the treatment of ocular disorders
US20250042931A1 (en) Compounds and methods for the treatment of ocular disorders
IL302174A (en) Compounds and methods for the treatment of eye disorders
US20260055110A1 (en) Compounds and methods for the treatment of dermal and ocular disorders
CN116940570A (zh) 用于治疗眼部病症的化合物和方法
HK40100091A (zh) 用於治疗眼部病症的化合物和方法